Fly News Breaks for January 8, 2019
Jan 8, 2019 | 07:40 EDT
Citi analyst Joel Beatty lowered his price target for Amarin to $20 after the company's 2019 revenue guidance came in lower than he expected. The analyst, however, continues to view Vascepa as an "attractive and differentiated cardiovascular risk reduction therapy." His peak sales estimate is now $2.5B, down from $3.0B previously.
News For AMRN From the Last 2 Days
There are no results for your query AMRN